Mold-Tek Packaging Releases Q4 FY26 Earnings Conference Call Transcript
Mold-Tek Packaging's Q4 FY26 earnings call transcript reveals strong growth in Pharma packaging (+37% in Q4, +200% FY) and Paints (+13.4% FY). The company plans to expand Pharma products and targets ₹55-60 crores for FY27. Capex for FY27 is projected at ₹80-85 crores, focusing on brownfield expansions. EBITDA per kg is expected to reach 42.5-43 in FY27.
The announcement details significant growth drivers, strategic expansions, and financial targets, which are material information for investors and can influence investment decisions.
The company reported strong growth in key segments like Pharma and Paints, discussed strategic expansions, and provided positive financial outlooks, indicating a favorable performance.
Mold-Tek Packaging Limited has released the transcript of its Q4 FY26 Earnings Conference Call, which was held on May 11, 2026. The call featured insights from Chairman and Managing Director, Mr. J. Lakshmana Rao, and was hosted by Emkay Global Financial Services Limited.
During the call, Mr. Rao highlighted improved performance and efficiencies following the consolidation of five Hyderabad units into two, leading to better EBITDA margins. He noted significant growth in the Pharma packaging segment, which grew by 37% in Q4 FY26 over the previous year and over 200% for the full year, with plans to expand the product range in this segment. The paints business also saw double-digit growth, contributing to an overall sales growth of 13.4% for the full year. While the Lubes segment faced a decline, it was offset by growth in Food and FMCG (25%) and Qpacks (25%).
Discussions also covered the Vibe collaboration, with pilot molds ready for new products, though commercial revenue is expected in FY27. The company reiterated its Pharma packaging target of ₹55-60 crores for FY27, compared to ₹34.4 crores in FY26. Growth in the Paint segment was attributed to new players like Grasim and a healthy recovery from Asian Paints, which saw over 17% growth. The decline in the Lubricant segment was explained by the loss of a major client, BPCL, which contributed significantly to past turnover.
Capex plans were detailed, with a focus on brownfield expansions and a reduced budget of ₹80-85 crores for FY27. The company anticipates reaching approximately 67,000-70,000 MTPA capacity by the end of FY27. Management also addressed concerns about raw material price fluctuations, stating that cost increases are being passed on to clients, strengthening client relationships. The company expects to maintain its gross margin levels. Future EBITDA per kg is projected to be around 42.5-43 for FY27 and potentially 43-45 for FY28, driven by operational efficiencies and increased capacity utilization.
Regarding the new Pharma packaging plant, construction is expected to commence after land possession, with commercial production anticipated by the beginning of the next calendar year (FY28). The company expects to cross the ₹1,000 crore sales mark in FY27 and potentially exceed ₹1,200 crores by FY28.
What to do with a filing like this
Mold-Tek Packaging Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mold-Tek Packaging Limited. Read the original for the full detail.